D. Boral Capital Reaffirms “Buy” Rating for Cytosorbents (NASDAQ:CTSO)

Cytosorbents (NASDAQ:CTSO)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a note issued to investors on Wednesday,Benzinga reports. They currently have a $10.00 target price on the medical research company’s stock.

Several other research firms have also recently weighed in on CTSO. HC Wainwright reissued a “neutral” rating and issued a $1.00 price target on shares of Cytosorbents in a research note on Thursday, May 15th. Wall Street Zen initiated coverage on shares of Cytosorbents in a research note on Wednesday, May 21st. They issued a “hold” rating for the company.

Cytosorbents Trading Down 1.7%

Shares of Cytosorbents stock opened at $1.18 on Wednesday. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.61. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.30 and a current ratio of 2.61. The firm has a 50-day simple moving average of $1.00 and a two-hundred day simple moving average of $1.01. The company has a market cap of $73.88 million, a P/E ratio of -4.21 and a beta of 1.05.

Cytosorbents (NASDAQ:CTSO) last issued its quarterly earnings results on Wednesday, May 14th. The medical research company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. Cytosorbents had a negative return on equity of 105.04% and a negative net margin of 41.77%. The firm had revenue of $8.73 million during the quarter, compared to analysts’ expectations of $9.01 million. As a group, equities analysts predict that Cytosorbents will post -0.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Cytosorbents

Several large investors have recently made changes to their positions in the stock. Goldman Sachs Group Inc. lifted its holdings in shares of Cytosorbents by 149.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock worth $63,000 after acquiring an additional 37,519 shares during the last quarter. Avenir Corp lifted its holdings in Cytosorbents by 63.1% during the 1st quarter. Avenir Corp now owns 5,044,918 shares of the medical research company’s stock worth $5,045,000 after buying an additional 1,950,972 shares in the last quarter. CM Management LLC lifted its holdings in Cytosorbents by 36.3% during the 1st quarter. CM Management LLC now owns 954,076 shares of the medical research company’s stock worth $954,000 after buying an additional 254,076 shares in the last quarter. Skylands Capital LLC lifted its holdings in Cytosorbents by 7.9% during the 1st quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company’s stock worth $3,003,000 after buying an additional 221,080 shares in the last quarter. Finally, Key Client Fiduciary Advisors LLC lifted its holdings in Cytosorbents by 127.0% during the 1st quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company’s stock worth $78,000 after buying an additional 43,900 shares in the last quarter. 32.87% of the stock is currently owned by institutional investors and hedge funds.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.